Canine Hepatic Neoplasia Study Guide

Overview and Clinical Importance

Hepatic neoplasia encompasses both primary and metastatic tumors affecting the liver in dogs. While primary liver tumors are relatively uncommon, representing only approximately 1.5% to 2.6% of all canine neoplasms, they carry significant clinical importance due to their variable prognosis and the liver's critical metabolic functions. Metastatic liver disease is approximately 2.5 times more common than primary hepatic tumors, making differentiation essential for treatment planning.

The liver's unique dual blood supply from the hepatic artery and portal vein makes it a common site for metastatic spread from gastrointestinal, pancreatic, splenic, and other primary tumors.

Classification of Hepatic Neoplasia

Hepatic tumors are classified based on their origin (primary vs. metastatic) and their morphologic pattern (massive, nodular, or diffuse).

Morphologic Classification

Primary Hepatic Tumor Classification

Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is the most common malignant primary liver tumor in dogs, accounting for 50-77% of all primary hepatobiliary tumors. It typically affects older dogs with an average age of 10-11 years. No definitive breed predisposition exists, though Scottish Terriers with progressive vacuolar hepatopathy have increased HCC risk (34% develop HCC).

HCC Morphologic Distribution and Metastatic Rates

HCC Prognosis and Prognostic Factors

Massive HCC with complete surgical resection: Median survival time (MST) greater than 1,460 days (more than 4 years). Studies report tumor-related mortality is 15.4 times higher in dogs without surgical treatment.

• Favorable factors: Left-sided tumor location, complete surgical excision, massive morphology
• Unfavorable factors: Right-sided location, elevated ALT/AST, incomplete excision, lethargy at presentation

Biliary (Bile Duct) Tumors

Bile duct carcinoma (cholangiocarcinoma) is the second most common malignant primary liver tumor in dogs. These tumors arise from bile duct epithelium and are most commonly intrahepatic (approximately 75% of cases).

Key Features of Cholangiocarcinoma

• Morphology: Relatively equally distributed between massive, nodular, and diffuse forms
• Metastatic rate: Very high (67-90%) - regional lymph nodes, lungs, peritoneum
• Gross appearance: Grey-white to yellow-brown solid or cystic masses with firm, fibrous texture
• Prognosis: Poor - survival approximately 6 months even with surgical resection

Neuroendocrine Tumors (Carcinoids) and Mesenchymal Tumors

Hepatic Carcinoids

• Age: Typically younger dogs (average 8-9.8 years)
• Morphology: Most commonly diffuse (67% of cases)
• Metastasis: Nearly 100% have metastasis at necropsy
• Prognosis: Poor - surgery rarely possible; chemotherapy generally ineffective

Hepatic Hemangiosarcoma

Hemangiosarcoma (HSA) can occur as primary hepatic tumor or, more commonly, as metastatic disease from splenic or cardiac HSA. Breeds predisposed include German Shepherds, Golden Retrievers, and Labrador Retrievers.

• Metastatic rate: 86-100% (typically present at diagnosis)
• Treatment: Liver lobectomy for massive form + doxorubicin-based chemotherapy
• Prognosis: Poor - MST 4-6 months with treatment

Clinical Presentation

Primary hepatobiliary tumors most commonly affect older dogs (average age 10-11 years). Clinical signs are often nonspecific and vague, and up to one-third of dogs with HCC are asymptomatic at diagnosis.

Diagnostic Approach

Laboratory Findings

Diagnostic Imaging

Abdominal ultrasound is the imaging modality of choice for initial evaluation. It allows assessment of tumor morphology, echogenicity, and guidance for FNA/biopsy. However, ultrasound cannot definitively differentiate benign from malignant lesions - histopathology is required.

Treatment

Liver lobectomy is the treatment of choice for massive hepatic tumors. The liver has remarkable regenerative capacity, and up to 70% of hepatic parenchyma can be safely removed.

Treatment Summary by Tumor Type